Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2024 | EORTC 1208 Minitub: a prospective registry of patients with SN positive melanoma

Alexander Van Akkooi, MD, PhD, Melanoma Institute Australia, Sydney, Australia, gives an overview of the EORTC 1208 Minitub study (NCT01942603), which evaluates outcomes in patients with melanoma, who have a minimal sentinel node (SN) tumor burden managed without complete lymph node dissection. The study reveals that SN tumor burden and AJCC stage are independent prognostic factors, suggesting that minimal SN tumor burden may not necessitate aggressive surgical intervention and could impact future staging systems. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.